Effect of high dose of telmisartan for hyper molucular adiponectin and insulin resistance in patients with type 2 diabetes complicated with hypertension.

Trial Profile

Effect of high dose of telmisartan for hyper molucular adiponectin and insulin resistance in patients with type 2 diabetes complicated with hypertension.

Completed
Phase of Trial: Phase III

Latest Information Update: 20 Jul 2012

At a glance

  • Drugs Telmisartan (Primary) ; Amlodipine
  • Indications Hypertension in diabetes; Type 2 diabetes mellitus
  • Focus Pharmacodynamics
  • Most Recent Events

    • 20 Jul 2012 Primary endpoint 'Adiponectin-levels' has been met according to results published in Advances in Therapy; at 3 months, telmisartan 80 mg/day significantly increased HMW adiponectin levels from baseline compared with telmisartan 40 mg/day + amlodipine.
    • 20 Jul 2012 Results published in Advances in Therapy.
    • 11 Feb 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top